Loading clinical trials...
Loading clinical trials...
A Phase Ib, Open-label, Two Arm Study of i.v. and Oral Panobinostat (LBH589) in Combination With i.v. Trastuzumab (Herceptin®) and i.v. Paclitaxel as Treatment for Adult Female Patients With HER2 Overexpressing Metastatic Breast Cancer (MBC)
Conditions
Interventions
IV LBH589
Oral LBH589
+2 more
Locations
7
United States
Novartis Investigative Site
Mobile, Alabama, United States
Novartis Investigative Site
Woodville, South Australia, Australia
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Liège, Belgium
Novartis Investigative Site
Macerata, MC, Italy
Novartis Investigative Site
Aviano, PN, Italy
Start Date
December 1, 2008
Primary Completion Date
August 1, 2010
Last Updated
December 19, 2020
NCT07347600
NCT07085767
NCT05660083
NCT07354022
NCT02422641
NCT06377852
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions